Outcomes
ADVERSE EVENTS, SECONDARY
Our primary endpoint was percent change in CTx from baseline to end of the study (after 16 weeks). The secondary endpoints were percent change in PINP from baseline to end of study (EOS), rate of decline of CTx and PINP, compliance and adherence to the treatments, AEs, and serious adverse events (SAEs).